Dystrophin Market to Reach USD 13.02 Billion By 2026 | Top Vendors: Solid Biosciences Inc, Catabasis Pharmaceuticals, Sarepta Therapeutics, Editas Medicine Inc, BioMarin Pharmaceutical Inc

According to the current analysis of Reports and Data, the global Dystrophin Market was valued at 0.60 billion in 2018 and is expected to reach USD 13.02 billion by year 2026, at a CAGR of 47% percent. The growth of the dystrophin market is more in countries such as U.S, Austria, Czech Republic, Denmark, Germany, Hungary, Israel, Italy, Norway, Portugal, Slovakia, South Korea, and the United Kingdom; where key muscular dystrophy drugs are available in the market.

The market is characterized by the entry of a large number of players that includes emerging companies, as well as healthcare giants. The primary factor, for the focus of market players, is the unaddressed demand for treatment of muscular dystrophy diseases for a long time. There are over 35 companies engaged in clinical trials for the launch of novel therapeutics for the treatment of DMD. However, owing to stringent regulation across the globe for drug approval, very few drug candidates have received approval by medicine regulatory bodies such as the US Food and Drug Administration (FDA), and European Commission.

Request for PDF Sample at: https://www.reportsanddata.com/sample-enquiry-form/1063

North America is expected to have a high demand on account of the product launches in the U.S. In 2017, North America dominated the dystrophin market in 2017, with a market share of 52.6; followed by Europe. The North America dystrophin market is estimated to be worth USD 45.6 billion by 2025. Factors such as high incidence of muscular dystrophy in the region, accelerated FDA approval of drug in the region, favorable funding scenario for research & development in field of DMD, high healthcare expenditure potential among the North American population, availability of medical reimbursement in the region are among key factors supporting the growth of dystrophin market in North America.

Further key findings from the report suggest
Exon Skipping accounted for 45.3% of the overall industry in 2017 and will witness high growth owing to anticipated adoption across the globe after regulatory approval in Europe and other parts of the world. However, low awareness about therapeutics in developing nations is expected to hamper its growth over the forecast period.

Emerging approaches for muscular dystrophy therapies is expected to witness significant rise at a CAGR of ~90% from 2016 to 2025 in light of favorable inclination of the industry as well as healthcare professionals towards the development of new therapies.

Asia Pacific market was valued at USD 14.1 million in 2017 and is expected to reflect significant growth during the forecast period owing it to anticipated drug launches in the region. Favorable scenario for research and development funds and the presence of various emerging players in the region is likely to promote market growth over the forecast period. As of 2017, there is a lack of well-established effective muscular dystrophy therapy in the region, which is a significant factor for the low market share of the region.

Key participants include PTC Therapeutics, Sarepta Therapeutics, BioMarin Pharmaceutical Inc, Wave Life Sciences, Bristol-Myers Squibb and Catabasis Pharmaceuticals among others. PTC Therapeutics has a market presence through its muscular dystrophy drugs under the brand name, Emflaza, and Translarna. As of 2017, PTC Therapeutics dominated the market followed by Sarepta Therapeutics.

Read more at: https://www.reportsanddata.com/report-detail/dystrophin-market

For this report, Reports and Data have segmented the global dystrophin market on the basis of product, approach, and region:

Product Outlook (Revenue, USD Million, 2016 - 2026)
Exondys51
Translarna
Emflaza
Others

Approach Outlook (Revenue, USD Million, 2016 - 2026)
Exon Skipping
Anti-Inflammatory Therapy
Stop Codon Read-Through
Others Approaches

Regional Outlook (Revenue, USD Million, 2016 - 2025)
North America
U.S.
Canada

Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe

Asia Pacific
China
Japan
India
Rest of Asia-Pacific

Rest of the World

Make an enqurie at: https://www.reportsanddata.com/make-enquiry-form/1063

We are a boutique market intelligence and strategic consulting firm dedicated to make an meaningful impact on businesses across the globe. Our stellar estimation and forecasting models have earned recognition across majority of the business forum across the globe. Our services are arrayed over diverse sectors and industries looking to expand in alternative regions and products.

40 Wall St. 28th floor New York City, NY 10005 United States

This release was published on openPR.